Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AON D21

Next Previous
X
Search
Drug Profile

AON D21

Alternative Names: AON-D21

Latest Information Update: 28 Sep 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aptarion Biotech
  • Class Anti-infectives; Nucleotide aptamers
  • Mechanism of Action Complement C5a receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Community-acquired pneumonia
  • No development reported Paroxysmal nocturnal haemoglobinuria

Most Recent Events

  • 28 Sep 2024 No recent reports of development identified for phase-I development in Paroxysmal-nocturnal-haemoglobinuria(In volunteers) in Germany (IV, Infusion)
  • 02 Feb 2024 Phase-II clinical trials in Community-acquired pneumonia (Adjunctive treatment) in United Kingdom (IV) (NCT05962606)
  • 27 Jul 2023 Aptarion Biotech plans phase-II trial for Community acquired pneumonia (In adults, In the elderly) in October 2023 (IV) (NCT05962606)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top